[go: up one dir, main page]

WO2021076176A3 - Liquid emulsion therapy for treating acute cannabinoid intoxication - Google Patents

Liquid emulsion therapy for treating acute cannabinoid intoxication Download PDF

Info

Publication number
WO2021076176A3
WO2021076176A3 PCT/US2020/018830 US2020018830W WO2021076176A3 WO 2021076176 A3 WO2021076176 A3 WO 2021076176A3 US 2020018830 W US2020018830 W US 2020018830W WO 2021076176 A3 WO2021076176 A3 WO 2021076176A3
Authority
WO
WIPO (PCT)
Prior art keywords
intoxication
treating acute
liquid emulsion
emulsion composition
lipid emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/018830
Other languages
French (fr)
Other versions
WO2021076176A2 (en
Inventor
Jack Donaldson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/US2020/018830 priority Critical patent/WO2021076176A2/en
Priority claimed from US16/795,019 external-priority patent/US11504326B2/en
Publication of WO2021076176A2 publication Critical patent/WO2021076176A2/en
Publication of WO2021076176A3 publication Critical patent/WO2021076176A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A lipid emulsion composition including soybean oil, egg lecithin, glycerol and, or osmolality and method for treating acute cannabinoid intoxication or intoxication from other substances, such as alcohol or other drugs, by orally or intravenously administering this composition according to a predetermine protocol to treat patients experiencing acute cannabinoid intoxication or intoxication from other substances. The lipid emulsion composition could be administered to the intoxicated patient orally or intravenously. In some embodiments, the lipid emulsion composition includes soybean oil, egg yolk phospholipids, and glycerin.
PCT/US2020/018830 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication Ceased WO2021076176A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2020/018830 WO2021076176A2 (en) 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962807345P 2019-02-19 2019-02-19
US62/807,345 2019-02-19
US16/795,019 2020-02-18
USPCT/US2020/018830 2020-02-18
PCT/US2020/018830 WO2021076176A2 (en) 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication
US16/795,019 US11504326B2 (en) 2019-02-19 2020-02-19 Lipid emulsion therapy for treating acute cannabinoid intoxication

Publications (2)

Publication Number Publication Date
WO2021076176A2 WO2021076176A2 (en) 2021-04-22
WO2021076176A3 true WO2021076176A3 (en) 2021-07-08

Family

ID=75538889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/018830 Ceased WO2021076176A2 (en) 2019-02-19 2020-02-19 Liquid emulsion therapy for treating acute cannabinoid intoxication

Country Status (1)

Country Link
WO (1) WO2021076176A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081626A1 (en) * 2005-06-14 2009-03-26 William Milgram System and method for assessing cognitive function and measuring treatment efficacy
US20150253344A1 (en) * 2014-03-05 2015-09-10 John Scott Perez Method and apparatus for real-time detection of human cannabinoid intoxication
US20180344666A1 (en) * 2015-11-13 2018-12-06 Resq Pharma Inc. Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081626A1 (en) * 2005-06-14 2009-03-26 William Milgram System and method for assessing cognitive function and measuring treatment efficacy
US20150253344A1 (en) * 2014-03-05 2015-09-10 John Scott Perez Method and apparatus for real-time detection of human cannabinoid intoxication
US20180344666A1 (en) * 2015-11-13 2018-12-06 Resq Pharma Inc. Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKSEL ET AL.: "Intravenous lipid emulsion therapy for acute synthetic cannabinoid intoxication: Clinical experience in four cases", CASE REPORTS IN EMERGENCY MEDICINE, vol. 2015, 2015, pages 1 - 5, XP055838504, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/criem/2015/180921.pdf> [retrieved on 20210506] *
INTRALIPID: "Lipid emulsions for intravenous nutrition", PRODUCT MONOGRAPH, 11 May 2017 (2017-05-11), pages 1 - 36, Retrieved from the Internet <URL:https://www.fresenius-kabi.com/en-ca/documents/lntralipid-PM-ENG.pdf> [retrieved on 20210506] *

Also Published As

Publication number Publication date
WO2021076176A2 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
Steven et al. Semifluorinated alkane eye drops for treatment of dry eye disease—a prospective, multicenter noninterventional study
PKC-DMES study group Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial
Aiello et al. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2
US9084801B2 (en) Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
Finsterer et al. Small fiber neuropathy
Zhang et al. 6-Gingerol attenuates macrophages pyroptosis via the inhibition of MAPK signaling pathways and predicts a good prognosis in sepsis
Benbow et al. Painful diabetic neuropathy
CA2838312C (en) Therapeutic application of parenteral krill oil
Chaudhary et al. Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis
KR20170086111A (en) Stabilized omega-3 ophthalmic compositions
US20160067204A1 (en) Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
Koizumi et al. Full-thickness macular hole formation in idiopathic parafoveal telangiectasis
AR090972A1 (en) METHOD TO TREAT AMD IN ANTI-VEGF THERAPY-RESISTANT PATIENTS
Kawahara Treatment of Dry Eye Disease (DED) in Asia: strategies for short tear film breakup time-type DED
BR112021021029A2 (en) Cannabidiol preparation, and, method for treating a patient suffering from attacks associated with tuberous sclerosis complex
Choi et al. Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin‐induced diabetic rats
Shetty et al. Management of ocular neuropathic pain with vitamin B12 supplements: a case report
US20180344666A1 (en) Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity
WO2021076176A3 (en) Liquid emulsion therapy for treating acute cannabinoid intoxication
EP2158915B1 (en) Acylglycerophospholipides for treating symptoms accompanying cancer
Sgrignoli et al. Comparison of topical 0.03% tacrolimus in almond and linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits
KR20240109998A (en) Delivery Methods for the Treatment of Brain and Central Nervous System Disorders
Nishida et al. Case of acquired night blindness in a hemodialysis patient
Martínez et al. Tamoxifen retinal toxicity. Monitoring by multimodal imaging study
US20140120171A1 (en) Therapeutic application of parenteral krill oil

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20875972

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20875972

Country of ref document: EP

Kind code of ref document: A2